Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) and Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.
Earnings and Valuation
This table compares Recursion Pharmaceuticals and Enlivex Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Recursion Pharmaceuticals | $58.84 million | 36.22 | -$463.66 million | ($1.80) | -2.28 |
| Enlivex Therapeutics | N/A | N/A | -$15.01 million | ($0.55) | -1.98 |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Recursion Pharmaceuticals and Enlivex Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Recursion Pharmaceuticals | 1 | 3 | 2 | 0 | 2.17 |
| Enlivex Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Recursion Pharmaceuticals currently has a consensus target price of $9.40, indicating a potential upside of 129.27%. Enlivex Therapeutics has a consensus target price of $13.00, indicating a potential upside of 1,092.66%. Given Enlivex Therapeutics’ higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Recursion Pharmaceuticals.
Profitability
This table compares Recursion Pharmaceuticals and Enlivex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Recursion Pharmaceuticals | -1,637.81% | -72.74% | -52.46% |
| Enlivex Therapeutics | N/A | -62.91% | -53.33% |
Insider & Institutional Ownership
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Recursion Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
Summary
Enlivex Therapeutics beats Recursion Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
